POINT Biopharma Reports Third Quarter 2021 Financial Results and Provides Business Update
12 nov. 2021 08h30 HE
|
POINT Biopharma
Initiated randomization phase of Phase 3 SPLASH study of PNT2002 in patients with metastatic castration-resistant prostate cancer (mCRPC) Expanded FAP alpha inhibitor platform and on track to file an...
POINT Biopharma and IONETIX Announce Ac-225 Supply Agreement
09 nov. 2021 08h30 HE
|
POINT Biopharma
INDIANAPOLIS and TORONTO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing...
POINT Biopharma and Kinectrics Announce Yb-176 Supply Agreement Enabling North American Production of n.c.a. Lu-177
29 oct. 2021 08h30 HE
|
POINT Biopharma
POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations on Dec 6, 2021 – register online at...
POINT Biopharma Releases New Data and Exercises Option for Best-in-Class FAP Inhibitor
28 sept. 2021 08h00 HE
|
POINT Biopharma
Unique FAP targeting warhead combined with Actinium-225 or Lutetium-177 demonstrated complete tumor regression and long-term survival in preclinical models Initiation of a Phase 1 therapeutic...
POINT Biopharma Announces Initiation of Randomization for its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC
23 sept. 2021 08h00 HE
|
POINT Biopharma
25 patient dosimetry and safety run-in met all pre-specified safety and efficacy criteria Initiated patient enrollment in Canada with additional countries to begin enrolling in 4Q21 INDIANAPOLIS,...
POINT Biopharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 08h00 HE
|
POINT Biopharma
INDIANAPOLIS, Sept. 07, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life...
POINT Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Update
13 août 2021 07h06 HE
|
POINT Biopharma
Strengthened the Company’s balance sheet by completing the business combination with Therapeutics Acquisition Corp (“RACA”), with gross proceeds from the transaction totaling approximately $286.7...
POINT Biopharma Announces Early Completion of enrollment and initial dosing in the Lead-In of its Phase 3 SPLASH study of PNT2002 for mCRPC
10 août 2021 16h01 HE
|
POINT Biopharma
INDIANAPOLIS, Aug. 10, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals,...
POINT Biopharma and Isotopia Announce Lutetium-177 Clinical Supply Agreement
21 juil. 2021 08h00 HE
|
POINT Biopharma
INDIANAPOLIS and PETACH TIKVA, Israel, July 21, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to...
POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company
30 juin 2021 16h05 HE
|
POINT Biopharma
Common stock to commence trading on the Nasdaq Capital Market on July 1, 2021 under the ticker symbol “PNT” Gross proceeds from the transaction totaled approximately $286.7 million INDIANAPOLIS,...